Pramlintide

What Pramlintide does

Pramlintide copies the hormone amylin and is approved as Symlin for adults with diabetes using mealtime insulin. With insulin, it can cause severe low blood sugar. Trials show modest glucose and weight benefits. Its short action means weekly amylin schedules cannot be copied. FDA lists Symlin products as discontinued.

• Symlin is approved as an add-on for adults with type 1 or type 2 diabetes who use mealtime insulin and still miss their sugar goals. (Drug label)
• In trials, it modestly improved blood sugar and weight over one year. (Studied in a trial)
• In small studies, a single dose reduced meal size and how much people ate. (Studied in a trial)
• Some users report fewer blood sugar spikes after meals and needing less insulin. (Reported by users)

Uses in the sources

• Approved as an add-on for adults with type 1 or type 2 diabetes using mealtime insulin when optimized insulin has not met blood sugar goals. (Drug label) (source)
• Studied for weight loss in obesity, alone and with other drugs. It has no FDA weight-loss indication. (Studied in a trial) (source)
• Three published cases describe pramlintide plus semaglutide or dulaglutide in type 1 diabetes and obesity. (Clinician-published) (source)

Pramlintide dosage

Typical reported dose: Type 1 diabetes: starts at 15 mcg before meals, up to 60 mcg

• Symlin label: type 1 diabetes: 15 mcg before each major meal, then 30 mcg before each major meal, then 45 mcg before each major meal, then 60 mcg before each major meal immediately before each major meal, under the skin. Drug label. Studied in: Adults with type 1 diabetes using mealtime insulin. (source)
• Symlin label: type 2 diabetes: 60 mcg before each major meal, then 120 mcg before each major meal immediately before each major meal, under the skin. Drug label. Studied in: Adults with type 2 diabetes using mealtime insulin. (source)
• Early trial: 30 mcg per meal: 30 mcg before each meal three times daily before meals, under the skin. Studied in a trial. Studied in: Adults with type 1 diabetes. (source)
• Early trial: 100 mcg per meal: 100 mcg before each meal three times daily before meals, under the skin. Studied in a trial. Studied in: Adults with type 1 diabetes. (source)
• Early trial: 300 mcg per meal: 300 mcg before each meal three times daily before meals, under the skin. Studied in a trial. Studied in: Adults with type 1 diabetes. (source)
• 30 mcg four times daily: 30 mcg subcutaneously four times daily four times daily, under the skin. Studied in a trial. Studied in: Insulin-using adults with type 2 diabetes. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to store Pramlintide

Comes as: Ready-to-use SymlinPen 60: 1.5 mL at 1,000 mcg/mL., Ready-to-use SymlinPen 120: 2.7 mL at 1,000 mcg/mL..

Mixed with: None. Symlin pens contain a ready-to-use sterile solution..

• Do not dilute or mix with insulin. Inspect for particles or discoloration.
• Use a new needle each time and remove it for storage. Never share a pen, even with a new needle.
• The pen’s 30-day limit applies only to the pen. No verified community powder-mixing schedule was found.

Before mixing: Unopened pens: refrigerate at 2–8°C and protect from light. Do not freeze; discard if frozen.

After mixing: After first use: refrigerate or keep at no more than 30°C; discard after 30 days even if refrigerated.

Pramlintide side effects and risks

Reported side effects

• Nausea: Type 1 label pool: 48% versus 17% placebo; type 2: 28% versus 12%., moderate. Persistent nausea needs clinician review; treatment may need to be reduced or stopped. (source)
• Vomiting: Type 1: 11% versus 7% placebo; type 2: 8% versus 4%., moderate. Repeated vomiting or inability to eat needs prompt review of fluids, glucose and insulin. (source)
• Appetite loss: Type 1: 17% versus 2% placebo; type 2: 9% versus 2%., moderate. Eating less changes mealtime insulin needs; monitor intake and glucose together. (source)
• Headache: Type 2 label pool: 13% versus 7% placebo., mild. Check glucose; persistent or severe headache needs assessment. (source)
• Severe low blood sugar with insulin: Type 1, first 3 months without an initial insulin cut: medically assisted events in 7.3% versus 3.3% placebo., serious. Starting treatment requires your clinician to reduce mealtime insulin, with frequent blood sugar checks. (source)
• Stomach pain: Type 2: 8% versus 7% placebo., moderate. Severe or persistent pain needs prompt assessment, especially with vomiting. (source)
• Fatigue: Type 1 and type 2 label pools: 7% versus 4% placebo., mild (source)
• Dizziness: Type 1: 5% versus 4% placebo; type 2: 6% versus 4%., moderate. Check glucose and avoid driving while symptoms persist. (source)
• Injection-site reactions: Postmarketing reports; frequency cannot be estimated., mild. Use room-temperature solution, rotate sites and check injection technique. (source)
• Pancreatitis: Reported after approval; frequency and causation are uncertain., serious. Severe persistent upper-abdominal pain, especially with vomiting, needs urgent assessment. (source)

Stop and get help if

• Confusion, seizure, fainting, or low blood sugar that does not recover: Follow your prescribed rescue plan. Call emergency services for severe symptoms or failure to recover.
• Severe persistent upper-belly pain, especially with vomiting: Stop pramlintide and seek urgent care for possible pancreatitis.
• Swollen face or throat, trouble breathing, or widespread hives: Stop the injection and seek emergency care.
• Repeated vomiting or inability to keep down food or fluids: Get urgent help with blood sugar, fluids and insulin. Do not inject pramlintide if you cannot eat.

Who should avoid it

• under18: Pediatric safety and effectiveness are not established; the label advises against pediatric use.
• pregnant: Human safety data are limited; rat studies found birth defects at high exposures.
• breastfeeding: Transfer into human milk, infant effects and milk production are unknown.
• tryingToConceive: Plan diabetes care with your clinician before pregnancy.
• gastroparesis: The label rules out use with gastroparesis, meaning slow stomach emptying. Pramlintide slows it further.
• other: The label rules out use if you cannot feel low blood sugar warning signs.
• other: Avoid after severe low blood sugar needing help within the past 6 months, or when episodes recur.
• other: The label rules out use after a serious allergy to pramlintide or any ingredient.
• other: The label excludes people with HbA1c above 9%, unreliable glucose checks or inability to follow insulin adjustments. HbA1c measures long-term blood sugar.
• eatingDisorderHistory: Appetite loss and nausea may worsen restrictive eating; this is not a label contraindication.
• pancreatitisHistory: Pancreatitis has been reported after approval; prior pancreatitis needs review before use.
• kidneyDisease: Kidney disease needs clinician review. No label dose change for creatinine clearance 15–89 mL/min. End-stage kidney disease has not been studied.
• liverDisease: Liver impairment has not been studied.
• surgeryPlanned: Fasting and illness affect dosing and insulin needs. If interrupted, the label requires restarting the initiation schedule.
• other: Visual or hand-function problems can cause dosing errors; the label calls for extra caution.
• other: Migraine-like attacks occurred in an IV provocation study. The risk with routine SC doses is not established.
• diabetes: Pramlintide supplements insulin; it cannot replace it. Mealtime insulin must be adjusted with close glucose monitoring.
• testedAthlete: No pramlintide-specific 2026 ruling was found. Confirm with the sport’s anti-doping body; accompanying insulin is prohibited.
• other: The label excludes people who need medicines that stimulate gut movement.

Interactions

• Insulin: Severe low blood sugar risk rises. When starting pramlintide, your clinician must reduce mealtime insulin and plan blood sugar checks. Inject separately; never mix.
• Sulfonylureas and meglitinides: These increase insulin release and can add to low-glucose risk; reassess the glucose-lowering plan.
• Time-sensitive oral medicines: For medicines needing rapid or threshold absorption, the label says at least 1 hour before or 2 hours after pramlintide.
• Warfarin and other critical oral medicines: Stomach emptying is delayed. No specific warfarin interaction trial was found; review timing and condition-specific monitoring.
• Medicines changing gut movement: The label advises against use with drugs that change gut movement or slow nutrient absorption.
• GLP-1 and GIP/GLP-1 drugs: Fullness and delayed stomach emptying may add up. 3 cases with type 1 diabetes and obesity leave combination safety uncertain.
• Other amylin agonists: Shared amylin effects may add nausea and slow stomach emptying. Cell studies do not establish combination safety.
• Drugs that increase low-glucose risk: These medicines can raise low blood sugar risk when taken together.
• Drugs that mask low-glucose symptoms: These can hide low blood sugar warning signs.
• Metreleptin: Obesity trials tested this pair, but neutralizing leptin antibodies raised concern. The combination has no obesity approval.

Product quality risks

• No independent study testing online pramlintide products or counterfeit Symlin pens was located.
• Other online peptide tests show why identity, content and contamination matter; those rates cannot be assigned to pramlintide.
• In three online semaglutide samples, purity was 7–14% and content 29–39% above the label; one contained elevated endotoxin. This was not pramlintide.
• FDA warns that poor compounding can cause contamination or too much or too little active drug.
• A research-use label and an HPLC purity number do not establish an injectable product’s sterility or dose.

What to expect

51 completed, terminated or active registered studies were found; 15 planned, withdrawn or unknown-status records were excluded. Early unregistered trials make this a minimum.

Key studies

• Early dose finding: 30–300 mcg: Meal glucose rises fell; the highest dose caused more nausea. (source)
• Four-week dose and meal timing: Several meal-based schedules improved short-term glucose markers. (source)
• Type 2 dose finding: Short-term glucose markers improved across the tested doses. (source)
• Type 1: one year plus extension: Pramlintide modestly improved glucose control without weight gain. (source)
• Type 1: 60 and 90 mcg: 60 mcg modestly improved HbA1c and weight over one year. (source)
• Type 1: fixed-insulin trial: This fixed-insulin trial showed a modest blood sugar effect. (source)

Pramlintide FAQ

• Is Pramlintide FDA-approved? Yes: Symlin / SymlinPen (add-on for type 1 or type 2 diabetes using mealtime insulin with inadequate control despite optimized insulin.). Approved 2005-03-16. All products are listed Discontinued; manufacture notices date to 2025-10-27. These listings do not establish real-time inventory or a safety-related approval withdrawal.
• How do people take it? Under the skin, immediately before each major meal. Source: drug label.
• What's the difference between Pramlintide and Semaglutide? Pramlintide: a diabetes medicine that copies a hormone released with insulin; Symlin products are discontinued. Semaglutide: a GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter. Why people pair them: two published cases combined fullness pathways for weight loss in type 1 diabetes and obesity.
• Can I take it with Semaglutide? Two published cases combined fullness pathways for weight loss in type 1 diabetes and obesity. No randomized trial of this pramlintide pair was located; nausea and insulin changes need close attention. Source: clinician-published. Ask a doctor before combining anything.
• Is it banned in sport? It is unclear (WADA 2026). No pramlintide-specific ruling found. The 2026 list does not name it; S0 depends on current approval and S4.4.2 covers accompanying insulin.
• How do I store it once opened? After first use: refrigerate or keep at no more than 30°C; discard after 30 days even if refrigerated.